LT4864B - Sapropelio trąšos ir jų gavimo būdas - Google Patents

Sapropelio trąšos ir jų gavimo būdas Download PDF

Info

Publication number
LT4864B
LT4864B LT2001004A LT2001004A LT4864B LT 4864 B LT4864 B LT 4864B LT 2001004 A LT2001004 A LT 2001004A LT 2001004 A LT2001004 A LT 2001004A LT 4864 B LT4864 B LT 4864B
Authority
LT
Lithuania
Prior art keywords
sapropel
peat
fertilizer
mixture
fertilizers
Prior art date
Application number
LT2001004A
Other languages
English (en)
Other versions
LT2001004A (lt
Inventor
Evaldas Gei�Toraitis
Antanas Ci�Nys
Original Assignee
Evaldas Gei�Toraitis
Antanas Ci�Nys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evaldas Gei�Toraitis, Antanas Ci�Nys filed Critical Evaldas Gei�Toraitis
Publication of LT2001004A publication Critical patent/LT2001004A/lt
Publication of LT4864B publication Critical patent/LT4864B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Description

Išradimas priklauso trąšų gamybos sričiai, būtent organinių trąšų mišiniams, į kurių sudėtį įeina sapropelis ir jų gavimo būdui. Šiuo būdu gautos trąšos naudojamos efektyviam dirvų tręšimui.
Sapropelis - tai ežerų dugne, esant deguonies trūkumui, iš tirpių ir kietų nuosėdų, veikiant biologiniamš procesams, per kelis tūkstantmečius susiformavusi organinė medžiaga. Seniai yra žinomas organinio sapropelio panaudojimas žemės ūkyje (L. Katkevičius, A. Ciūnys, E. Bakšienė Ežerų sapropelis žemės ūkiui”, Vilnius, 1998).
Žinomas organmineralinių sapropelio trąšų gavimo būdas, kai sapropelio pulpą sutirština nusodintuve, pašalina pagrindinę nuskaidrinto vandens masę ir į sutirštintą sapropelio pulpą deda mineralinius priedus, būtent skalūnų pelenus (buv. TSRS a.l. Nr. 1724657).
Aprašyto sapropelio trąšų gavimo būdo trūkumas yra ilgai trunkantis šių trąšų paruošimas, o šiuo būdu gautos trąšos lėtai mineralizuojasi ir maisto medžiagas atiduoda palaipsniui, be to, šiose trąšose yra mažai hidrolizuojamų medžiagų.
Žinomos sapropelio trąšos, susidedančios iš sapropelio ir organinių ir/arba mineralinių priedų, kaip organiniai priedai gali būti durpės ir/arba skiedros, ir/arba pjuvenos, ir u.oa mėšlas, o kaip mineraliniai priedai gali būti ceolitas ir/arba mineralinės trąšos, ir/arba šlakas, ir/arba karbonatinis sapropelis. Sapropelio trąšose priedai sudaro nurodytus masės % : durpės su drėgminiu imlumu 1000% 30;Fosforo trąšos 0,4
Kalio trąšos 0,2
Azoto trąšos 0,25
Likusi dalis: Karbonatinis sapropelis (Rusijos patentas Nr. 2041866, 1994 01 20, C05F 7/00).
Žinomas sapropelio trąšų gavimo būdas, kai išimtą iš ežero sapropelį aikštelėje paskleidžia sluoksniu ir periodiškai maišant džiovina pridedant priedų. Žiemą sapropelį šaldo ir sudeda į m aukščio krūvas, kad pavasarį po šalčių sapropelio masės drėgnis būtų apie 40 %
Maišymo metu į sapropelį įveda mineralinius ir/arba organinius priedus, tokius kaip durpes, 2 LT 4864 B ir/arba skiedras, ir/arba pjuvenas, ir/arba ceolitą, ir/arba mineralines trąšas, ir/arba šlaką, ir/arba karbonatinį sapropelį. Po to sapropelį valo nuo pašalinių priemaišų, mala, džiovina iki jo drėgnis siekia 10-40% bei granuliuoja (Rusijos patentas Nr. 2041866, 1994 01 20, C05F 7/00).
Žinomose sapropelio trąšose dedama 30 masės % durpių su drėgminiu imlumu 1000%, tai atitinka sausosios medžiagos durpių 9 masės %. Žinomo sapropelio trąšų gavimo būdas ilgas ir brangus, nes šiuo būdu gautų trąšų kompozicijoje esantis mineralinių ir organinių medžiagų masių santykis neužtikrina greito sapropelio trąšų džiovinimo proceso, be to, reikalinga įranga trąšų malimui, granuliavimui bei jų pergabenimui nuo vienos apdorojimo operacijos prie kitos. Gautos šiuo būdu trąšos nepakankamai efektyvios, nes granulėse esančios maisto medžiagos lėtai atiduodamos dėl mažo granulių vandens imlumo.
Išradimu siekiama supaprastinti sapropelio trąšų gavimo būdą bei pagerinti sapropelio trąšų efektyvumą.
Uždavinio sprendimo esmė yra ta, kad sapropelio trąšose, susidedančiose iš sapropelio ir durpių mišinio, nauja yra tai, kad sapropelio ir durpių sausųjų medžiagų masių santykis mišinyje yra ribose nuo 1 : 1 iki 1 : 0,5.
Sapropelio gavimo būde, apimančiame sapropelio išėmimą iš ežero, jo paskleidimą sluoksniu aikštelėje, džiovinimą ir džiovinimo metu periodiškai maišant organinių priedų, pavyzdžiui, durpių į sapropelį įvedimą, nauja yra tai, kad sapropelio ir durpių sausųjų medžiagų masių santykį mišinyje palaiko ribose nuo 1 : 1 iki 1 : 0,5.
Sapropelio džiovinimo metu jo sumaišymas su durpėmis užtikrinant sausųjų medžiagų masių santykį nuo 1 : 1 iki 1 : 0,5 pagreitina sapropelio džiovinimą, tuo pačiu ir sapropelio trąšų gavimą bei pagerina gautų trąšų efektyvumą. Gauta mišinio masė puri, biri, struktūringa, pasižymi geromis absorbcinėmis sąvybėmis. Šis trąšų gamybos būdas yra pigus, jo realizavimas nereikalauja sudėtingos įrangos. Gautose trąšose esanti durpių dalis pagreitina sapropelio mineralizaciją, padidina lengvai hidrolizuojamų medžiagų bei humusinių rūgščių kiekį, o esanti sapropelio dalis sulėtina durpių mineralizaciją, neleidžia išgaruoti išsiskiriančioms augalų maisto medžiagoms
Trąšų optimalus džiovinimo laikas ir trąšų efektyvumas buvo nustatytas įvertinus žemiau aprašytus bandymus.
Bandymais buvo nustatyti sapropelio, durpių bei šių medžiagų mišinių džiovinimo duomenys, kurie pateikti 1 lentelėje.
lentelė
Bandymų variantai Būklė Džiovinimo laikas paromis' ir medžiagos drėgnis %
Šviežias 5 paros 10 parų 20 parų 30 parų 40
parų
1. Sapropelis (S) Tešlos 92 91 86 79 72 64
Konsist.
2. Durpės (D) Puri 73 69 47 34 27 28
3. S+D 1:1 Tirštos 89 87 81 69 56 51
tesi. kons.
4. S+D 1:2 Biri 87 84 70 62 54 48
5. S+D 1:3 Puri 82 79 63 55 49 36
6. S+D 1:0,5 Tirštos 90 89 84 73 66 58
Tešlos
konsist.
lentelės duomenys rodo, kad sumaišytas sapropelis su durpėmis greičiau džiūsta ir jo struktūra pasidaro puri. Greičiausiai džiūsta durpės ir tas mišinys, kur durpių daugiausiai, t.y. S+D 1:3. Tačiau šis sapropelio ir durpių santykis nėra efektyviausias augalams. Siekiant įvertinti sapropelio ir durpių bei jų mišinio kaip trąšų vertingumą, buvo atlikti bandymai, nustatant šių medžiagų toksiškumą. Kuo mažesnis trąšų toksiškumas, tuo didesni augalų dygimo energija, daigumas ir augimas. Pagal Valstybinį standartąNr.5055-56 buvo nustatyta agurkų veislės “Alfa” sėklų dygimo energija ir daigumas. Escherichia coli bakterinė kultūra buvo įvesta į vandeninę tiriamosios medžiagos ištrauką santykiu (1 : 1). Bandymo rezultatai pateikti 2 lentelėje.
lentelė. Sapropelio - durpių trąšų vertingumo nustatymas
Bandymų variantai Dygimo energija % Daigumas % Augimas pagal E.c.
1. Sapropelis (S) +9 +12 +2
2. Durpės (D) +3 1 -2 -2
3. S + D 1:1 +6 +5 +4
4. S + D 1:2 +3 +3 +3
5. S + D 1:3 +2 +1 +1
6. S + D 1:0,5 +8 +7 +5
lentelės duomenys rodo, kad efektyviausia trąša yra sapropelio ir durpių mišinys 1 : 0,5, tačiau šios trąšos lėtokai džiūsta. Įvertinus abiejų lentelių duomenis buvo nustatyta, kad geriausias trąšų efektyvumas ir palygint neilgas džiovinimo laikas pasiekiam·- Yiant sapropelį su durpėmis sausųjų medžiagų masės santykiu apie 1:1. Toks mišinys gerai išdžiūsta ir gaunama efektyvi trąša.
Pasiūlytos sapropelio trąšos susideda iš sapropelio ir durpių mišinio, kuriame sapropelio ir durpių sausųjų medžiagų masių santykis mišinyje yra nuo 1 : 1 iki 1 : 0,5.
Trąšų gavimo būdas. Nustatomas pradinių medžiagų t.y. sapropelio ir durpių, iš kurių bus gaminamos trąšos, drėgnis. Žinomais literatūroje aprašytais būdais (payzdžiui, sapropelio sausųjų medžiagų kiekis, esant skirtingam žaliavos drėgniui, yra pateiktas grafiko pavidale knygoje L. Katkevičius, A. Ciūnys, E. Bakšienė “Ežerų sapropelis žemės ūkiui”, Vilnius, 1998, 50 psl.) nustatomas santykis tarp atitinkamo drėgnio žaliavos ir sausųjų medžiagų kiekio. Sis santykis pateikiamas 3 lentelėje.
lentelė.
Žaliavos drėgnis, %. Sausųjų medžiagų kiekis, kg/mJ
90% 100 kg/m3
80% 220 kg/m3
70% 360 kg/m3
65% 590 kg/m3
50% 670 kg/m3
40% 820 kg/ m3
30% . 960 kg/m3
Pagal pateiktą lentelę, esant sapropelio drėgniui 70%, sausųjų medžiagų kiekis yra 360 kg/m3, o durpių drėgniui esant apie 40%, sausųjų medžiagų kiekis yra 820 kg/m3, todėl, norint pasiekti minėtų sausųjų medžiagų santykį 1:1, sapropelio kiekį reikia padidinti ne mažiau kaip dvigubai. Esant nurodytam pradinių medžiagų drėgmiui dedama 1 m3 durpių ir 2 m3 sapropelio, po to nurodytu santykiu sudėtos medžiagos mechaniškai sumaišomos. Vėliau mišinys džiovinamas apie 15 parų, kol mišinio drėgnis pasiekia apie 50%.
Pasiūlytų sapropelio trąšų gavimo būdas detaliau paiškintas pateiktuoses pavyzdžiuose.
pavyzdys. Valant užpelkėjusius ežerus iškasamos durpės, kurios būna susiformavusios ežerų pakraščiuose. Durpės vienkaušiu ekskavatoriumi supilamos ant kranto į 2 - 3 m aukščio krūvas. Durpės krūvose greitai išdžiūsta (po 20 dienų jų drėgnis siekia 30 — 4u ir gali būti naudojamos trąšoms gaminti.
Sapropelis kuopiamas atskirai, dažniausiai pulpos pavidale siurbiamas žemsiurbe .> ir plastmasiniais vamzdžiais arba polietileninėmis rankovėmis (žarnomis) transportuojamas į sėsdintuvus, kur supilamas 0,5 m storio sluoksniu. Nuleidus iš sėsdintuvo vandenį sapropelio drėgnis siekia 80 - 85%.
Išdžiūvusios durpės vežamos prie sėsdintuvų, pilamos 0,3 - 0,4 m storio sluoksniu ant sapropelio sluoksnio ir ekskavatoriumi su juo sumaišomos. Po to mišinys dar džiovinamas apie 15 parų. Kai jo drėgnis siekia apie 50%, trąšų mišinys gali būti fasuojamas arba išvežamas autotransportu laukams tręšti.
pavyzdys. Sapropelio ir durpių gavyba vykdoma analogiškai aprašytam pirmajame pavyzdyje. Sapropelis sėsdintuve paliekamas džiūti 15-18 parų, kol jo paviršius sutrūkinėja (jo drėgnis siekia apie 70%). Prie sėsdintuvo atvežamos sausos durpės. Sapropelio ir durpių 6 LT 4864 B maišymas vykdomas betono (ar panašia) maišykle (apie 2/3 tūrio sudaro sapropelis, 1/3 durpės, kad sausųjų medžiagos santykis išliktų 1:1). Mišinio drėgnis siekia 50 - 45%. Po kelių (5-8) parų drėgmė dar sumažėja, mišinys pasidaro purus, birus, jo granulių dydis 0,3 0,8 cm. Mišinys fasuojamas į maišelius.
pavyzdys. Užpelkėjusioje ežero pakrantėje pradžioje vienkaušiu ekskavatoriumi kasamos durpės ir supilamos į 2 - 3 m aukščio krūvas. Po to iš gilesnių sluoksnių kasamos žemiau esantis sapropelis, kraunamas į traktorines priekabas ir išvežamas į sandėliavimo aikštelę, kur paskleidžiamas 0,5 m storio sluoksniu. Po 10 parų sapropelio paviršius sutrūkinėja, jo drėgnis siekia apie 70 %. Tuomet atvežamos išdžiūvusios durpės ir maišomos su sapropeliu pirmajame arba antrajame pavyzdžiuose aprašytu būdu.

Claims (2)

  1. IŠRADIMO APIBRĖŽTIS
    1. Sapropelio trąšos, susidedančios iš sapropelio ir durpių mišinio, besiskiriančios tuo, kad sapropelio ir durpių sausųjų medžiagų masių santykis mišinyje yra nuo 1 : 1 iki
    1 : 0,5.
  2. 2. Sapropelio trąšų pagal 1 punktą gavimo būdas, apimantis sapropelio išėmimą iš ežero, jo paskleidimą sluoksniu aikštelėje, džiovinimą ir džiovinimo metu, periodiškai maišant, durpių įvedimą į sapropelį, besiskiriantis tuo, kad sapropelio ir durpių sausųjų medžiagų masių santykį mišinyje palaiko nuo 1 : 1 iki 1 : 0,5.
LT2001004A 1998-07-06 2001-01-16 Sapropelio trąšos ir jų gavimo būdas LT4864B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9184798P 1998-07-06 1998-07-06

Publications (2)

Publication Number Publication Date
LT2001004A LT2001004A (lt) 2001-07-25
LT4864B true LT4864B (lt) 2001-11-26

Family

ID=22229932

Family Applications (2)

Application Number Title Priority Date Filing Date
LT2000123A LT4854B (lt) 1998-07-06 2000-12-22 Bifenilsulfonamidai kaip dvigubi angiotenzino ir endotelino receptorių antagonistai
LT2001004A LT4864B (lt) 1998-07-06 2001-01-16 Sapropelio trąšos ir jų gavimo būdas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LT2000123A LT4854B (lt) 1998-07-06 2000-12-22 Bifenilsulfonamidai kaip dvigubi angiotenzino ir endotelino receptorių antagonistai

Country Status (29)

Country Link
EP (2) EP1094816B1 (lt)
JP (2) JP2002519380A (lt)
KR (1) KR20010083092A (lt)
CN (1) CN1149196C (lt)
AT (1) ATE416772T1 (lt)
AU (1) AU767456B2 (lt)
BG (1) BG65404B1 (lt)
BR (1) BR9911621A (lt)
CA (1) CA2336714A1 (lt)
CZ (1) CZ200172A3 (lt)
DE (1) DE69940063D1 (lt)
DK (1) DK1094816T3 (lt)
EE (1) EE200100006A (lt)
ES (1) ES2318899T3 (lt)
GE (1) GEP20033114B (lt)
HU (1) HUP0104634A3 (lt)
ID (1) ID26984A (lt)
IL (1) IL140622A0 (lt)
LT (2) LT4854B (lt)
LV (1) LV12639B (lt)
NO (1) NO20010062L (lt)
NZ (1) NZ508118A (lt)
PL (2) PL201048B1 (lt)
PT (1) PT1094816E (lt)
RU (1) RU2001103044A (lt)
SK (1) SK18822000A3 (lt)
TR (1) TR200100149T2 (lt)
WO (1) WO2000001389A1 (lt)
ZA (1) ZA200006772B (lt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT6043B (lt) 2012-08-27 2014-06-25 Uab "Mibarsas" Organinės trąšos sapropelio pagrindu ir jų gamybos būdas
LT7101B (lt) 2024-01-16 2024-10-25 Steponavičius Petras Organinės trąšos sapropelio pagrindu ir jų gamybos būdas, panaudojant susmulkintus šiaudus, aukštapelkines durpes ir hidrogelį

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
ES2318899T3 (es) * 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1741713A3 (en) * 1999-12-15 2009-09-09 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AU2456701A (en) * 1999-12-31 2001-07-16 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
EP1353727A2 (en) * 2000-12-01 2003-10-22 Novartis AG Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
GEP20074098B (en) 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
HRP20040343A2 (en) 2001-10-18 2005-08-31 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2004037181A2 (en) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7754755B2 (en) 2004-09-23 2010-07-13 Bristol-Myers Squibb Company Inhibitors of 15-lipoxygenase
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
JP4912314B2 (ja) 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
DE602006020327D1 (de) 2005-01-19 2011-04-07 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
ATE421518T1 (de) 2005-02-10 2009-02-15 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006021306D1 (lt) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1812411A2 (en) * 2005-07-05 2007-08-01 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
US7534804B2 (en) 2005-08-24 2009-05-19 Bristol-Myers Squibb Company Benzoxazole inhibitors of 15-lipoxygenase
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
JP2009506119A (ja) 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
BRPI0708507A2 (pt) * 2006-03-03 2011-05-31 Torrent Pharmaceuticals Ltd Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta
WO2007109456A2 (en) * 2006-03-16 2007-09-27 Pharmacopeia, Inc. Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JP5215300B2 (ja) 2006-07-12 2013-06-19 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2665476A1 (en) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9078888B2 (en) 2007-01-22 2015-07-14 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PT2173737E (pt) 2007-07-17 2012-03-19 Bristol Myers Squibb Co Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US7834041B2 (en) 2007-09-07 2010-11-16 Theravance, Inc. Dual-acting antihypertensive agents
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
CN101896470B (zh) 2007-12-11 2013-04-10 施万制药 双重作用的苯并咪唑衍生物和其作为抗高血压药剂的用途
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
EP2297113A1 (en) 2008-04-29 2011-03-23 Theravance, Inc. Dual-acting antihypertensive agents
EP2805939B1 (en) 2008-05-19 2018-06-27 Merck Sharp & Dohme Corp. Heterocyclic compounds as factor IXA inhibitors.
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2009155448A1 (en) * 2008-06-20 2009-12-23 Ligand Pharmaceuticals Inc. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ595723A (en) * 2009-03-17 2012-10-26 Daiichi Sankyo Co Ltd Amide derivative
US20100256153A1 (en) 2009-03-27 2010-10-07 Bristol-Myers Squibb Company Methods for preventing or reducing risk of mortality
HUE033494T2 (en) * 2009-03-31 2017-12-28 Ligand Pharm Inc Biphenylsulfonamide Endothelin and Angiotensin II Receptor Antagonist for Glomerulosclerosis
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2535347C3 (ru) * 2009-05-26 2019-05-14 ЭббВи Айэленд Анлимитед Компани Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
ES2441419T3 (es) 2009-07-22 2014-02-04 Theravance, Inc. Agentes antihipertensivos de doble acción basados en oxazol
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
CA2774573A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
BR112012011726A2 (pt) 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
WO2011060290A2 (en) 2009-11-13 2011-05-19 Bristol-Myer Squibb Company Immediate release tablet formulations
CN101891735B (zh) * 2009-11-25 2012-07-18 北京理工大学 联苯磺胺异噁唑类化合物、合成方法及用途
CN101921265B (zh) * 2009-11-25 2012-07-04 北京理工大学 联苯酰胺四唑类化合物、合成方法及用途
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PT2642999T (pt) 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Métodos de tratamento que utilizam inibidores seletivos de bcl-2
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CA2853024C (en) 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
WO2013150416A1 (en) 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
CA2876359C (en) 2012-06-11 2020-01-21 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl] pyridine-3-sulfonamide
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CN110840870A (zh) 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2014039412A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
ES2869286T3 (es) 2012-11-20 2021-10-25 Lexicon Pharmaceuticals Inc Inhibidores del cotransportador 1 de sodio-glucosa
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
CN105008366B (zh) 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
ES2616025T3 (es) 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolotriazinas como inhibidores de canales de iones potasio
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014145331A1 (en) 2013-03-15 2014-09-18 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3055300B1 (en) 2013-10-09 2018-03-07 Pfizer Inc Antagonists of prostaglandin ep3 receptor
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
KR101772836B1 (ko) 2014-03-17 2017-08-29 화이자 인코포레이티드 대사 및 관련 장애의 치료에 사용하기 위한 디아실글리세롤 아실트랜스퍼라제 2 억제제
BR112016023117B1 (pt) 2014-04-04 2023-02-07 Pfizer Inc Compostos de heteroarila ou arila bicíclicos fundidos
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
CN104761548B (zh) * 2015-04-27 2017-09-12 梯尔希（南京）药物研发有限公司 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法
JP2018515480A (ja) 2015-05-05 2018-06-14 ファイザー・インク ２−チオピリミジノン
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
TN2017000485A1 (en) 2015-06-17 2019-04-12 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
AU2016305590A1 (en) 2015-08-13 2018-02-15 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
KR102029124B1 (ko) 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
CN105481844A (zh) * 2015-12-08 2016-04-13 梁彦云 一种治疗高血压的药物组合物
CN108473469B (zh) 2015-12-29 2020-11-03 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN106188115A (zh) * 2016-07-13 2016-12-07 北京理工大学 廉价高效合成2‑二羟硼基‑n‑二甲异噁唑基‑n‑甲氧乙氧甲基苯磺酰胺的新方法
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
CN109715637B (zh) 2016-07-22 2022-04-05 百时美施贵宝公司 葡萄糖激酶激活剂及其使用方法
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN114788823A (zh) 2016-10-13 2022-07-26 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
EP3592730B1 (en) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
ES2897200T3 (es) 2017-05-31 2022-02-28 Amplio Pharma Ab Una composición farmacéutica que comprende una combinación de metotrexato y novobiocina, y el uso de la composición en terapia
EP3489222A1 (en) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazine salts, production processes and uses
FI3488868T3 (fi) 2017-11-23 2023-10-20 Medac Ges Fuer Klinische Spezialpraeparate Mbh Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
BR112021003039A2 (pt) 2018-08-31 2021-05-18 Pfizer Inc. combinações para o tratamento de nash/nafld e doenças relacionadas
SG11202102498UA (en) 2018-09-26 2021-04-29 Lexicon Pharmaceuticals Inc Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
BR112021006132A2 (pt) 2018-10-04 2021-07-20 Travere Therapeutics, Inc. compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
PL4097099T3 (pl) 2020-02-07 2024-11-04 Gasherbrum Bio, Inc. Heterocykliczne agonisty glp-1
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
PT4188389T (pt) 2020-07-27 2025-10-07 Astrazeneca Ab Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
EP4393920A4 (en) * 2021-08-26 2025-12-24 Shanghai Hansoh Biomedical Co Ltd BIOLOGICAL ANTAGONIST CONTAINING AN AROMATIC RING, ITS PREPARATION PROCESS AND ITS USE
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
WO2023066348A1 (zh) * 2021-10-21 2023-04-27 年衍药业（上海）有限公司 一种双重拮抗剂及其用途
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
EP4444708B1 (en) 2021-12-06 2025-07-30 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
EP4469038A1 (en) 2022-01-26 2024-12-04 Astrazeneca AB Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023224963A1 (en) * 2022-05-16 2023-11-23 Aria Pharmaceuticals, Inc. Dual-acting angiotensin and endothelin receptor antagonists
IL319486A (en) 2022-10-07 2025-05-01 Pfizer HSD17B13 Inhibitors and/or Retarders
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
CN115745983A (zh) * 2022-11-23 2023-03-07 深圳信立泰药业股份有限公司 一种血管紧张肽和内皮肽受体拮抗剂及其应用
EP4634180A1 (en) 2022-12-15 2025-10-22 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
CN120731201A (zh) 2022-12-16 2025-09-30 辉瑞公司 含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途
AU2024224496A1 (en) * 2023-02-24 2025-10-02 Changzhou Hansoh Pharmaceutical Co., Ltd. Salt containing aromatic ring derivative antagonist, preparation method therefor, and application thereof
AU2024250528A1 (en) 2023-04-14 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
CN116731004B (zh) * 2023-06-08 2025-11-25 李能刚 作为血管紧张素和内皮素受体双重拮抗剂的联苯磺酰胺
WO2025099566A1 (en) 2023-11-08 2025-05-15 Pfizer Inc. A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid
WO2025149789A1 (en) * 2024-01-09 2025-07-17 Procos S.P.A. Process for the preparation of sparsentan
WO2025163561A1 (en) 2024-02-01 2025-08-07 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
US20250326741A1 (en) 2024-04-22 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1724657A1 (ru) 1990-02-26 1992-04-07 Научно-Производственный Кооператив "Охрана Природы" Способ приготовлени сапропелевого удобрени
RU2041866C1 (ru) 1994-01-20 1995-08-20 Акционерное предприятие "Сапропель-Неро" Способ добычи и получения сапропелевого удобрения

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5240928A (en) * 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
WO1991011999A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
DE59107440D1 (de) * 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
FR2681067B1 (fr) 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
IE912956A1 (en) * 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
US5250548A (en) * 1990-09-10 1993-10-05 Abbott Laboratories Angiotensin II receptor antagonists
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
TW274551B (lt) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
CA2079982A1 (en) * 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
US5674883A (en) * 1992-02-07 1997-10-07 Roussel Uclaf Derivatives of pyridone, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
GB2264710A (en) * 1992-03-04 1993-09-08 Merck & Co Inc Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5256658A (en) 1993-01-15 1993-10-26 Ortho Pharmaceutical Corporation Angiotensin II inhibitors
DE4300912A1 (de) 1993-01-15 1994-07-21 Merck Patent Gmbh Chinazolinderivate
ES2126061T3 (es) 1993-03-24 1999-03-16 American Home Prod Piridopirimidinas substituidas como antihipertensores.
DE4320432A1 (de) 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
ZA945190B (en) 1993-07-30 1995-02-24 Kotobuki Seiyaku Co Ltd Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
US5674879A (en) 1993-09-24 1997-10-07 G.D. Searle & Co. Compositions including and methods of using conformationally restricted angiotensin II antagonist
US5438136A (en) 1993-11-02 1995-08-01 Merck & Co., Inc. Benzo-fused macrocycles promote release of growth hormone
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
IL116916A (en) * 1995-02-06 2000-09-28 Bristol Myers Squibb Co Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same
ATE243203T1 (de) * 1995-04-04 2003-07-15 Texas Biotechnology Corp Thienyl-, furyl-, pyrrolyl- und biphenylsulfonamide und derivate zur modulation der endothelin-aktivität
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997033886A1 (en) * 1996-03-12 1997-09-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
IT1283620B1 (it) 1996-04-19 1998-04-22 Luso Farmaco Inst "pirimidin-4-oni n-3 sostituiti ad attivita' aii antagonista"
JPH09291078A (ja) 1996-04-25 1997-11-11 Kyorin Pharmaceut Co Ltd オルトメトキシフェニルピペラジニルアルコキシアリール基を有する新規イミダゾール誘導体及びその製造法
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5846985A (en) * 1997-03-05 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
ES2318899T3 (es) * 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1724657A1 (ru) 1990-02-26 1992-04-07 Научно-Производственный Кооператив "Охрана Природы" Способ приготовлени сапропелевого удобрени
RU2041866C1 (ru) 1994-01-20 1995-08-20 Акционерное предприятие "Сапропель-Неро" Способ добычи и получения сапропелевого удобрения

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. KATKEVIČIUS, A.CIŪNYS, E.BAKŠIENĖ: "Ežerų sapropelis žemės ūkiui", pages: 30 - 50

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT6043B (lt) 2012-08-27 2014-06-25 Uab "Mibarsas" Organinės trąšos sapropelio pagrindu ir jų gamybos būdas
LT7101B (lt) 2024-01-16 2024-10-25 Steponavičius Petras Organinės trąšos sapropelio pagrindu ir jų gamybos būdas, panaudojant susmulkintus šiaudus, aukštapelkines durpes ir hidrogelį

Also Published As

Publication number Publication date
AU5088899A (en) 2000-01-24
LV12639A (lv) 2001-04-20
BG105205A (en) 2001-09-28
LT4854B (lt) 2001-11-26
PL346443A1 (en) 2002-02-11
ZA200006772B (en) 2002-02-20
CA2336714A1 (en) 2000-01-13
HUP0104634A3 (en) 2002-11-28
NO20010062L (no) 2001-03-05
EE200100006A (et) 2002-06-17
CZ200172A3 (cs) 2001-08-15
PL203771B1 (pl) 2009-11-30
ES2318899T3 (es) 2009-05-01
JP2002519380A (ja) 2002-07-02
LT2001004A (lt) 2001-07-25
EP1094816A1 (en) 2001-05-02
EP1094816B1 (en) 2008-12-10
AU767456B2 (en) 2003-11-13
WO2000001389A1 (en) 2000-01-13
GEP20033114B (en) 2003-11-25
LV12639B (lv) 2001-09-20
DE69940063D1 (de) 2009-01-22
NZ508118A (en) 2003-07-25
PL201048B1 (pl) 2009-03-31
HUP0104634A2 (en) 2002-10-28
ATE416772T1 (de) 2008-12-15
JP2010209096A (ja) 2010-09-24
TR200100149T2 (tr) 2001-10-22
PT1094816E (pt) 2009-03-10
SK18822000A3 (sk) 2001-12-03
BR9911621A (pt) 2001-10-16
IL140622A0 (en) 2002-02-10
EP2002837A1 (en) 2008-12-17
RU2001103044A (ru) 2003-08-10
CN1308536A (zh) 2001-08-15
DK1094816T3 (da) 2009-04-06
BG65404B1 (bg) 2008-06-30
KR20010083092A (ko) 2001-08-31
EP1094816A4 (en) 2001-12-19
NO20010062D0 (no) 2001-01-05
CN1149196C (zh) 2004-05-12
LT2000123A (lt) 2001-07-25
ID26984A (id) 2001-02-22

Similar Documents

Publication Publication Date Title
LT4864B (lt) Sapropelio trąšos ir jų gavimo būdas
US5501718A (en) Method to produce substitute for peat moss
CN101390468B (zh) 红层砂岩边坡创面人工土壤的制备方法
CN101390470B (zh) 红层砂泥岩互层边坡创面人工土壤的制备方法
Joost et al. Revegetation and minesoil development of coal refuse amended with sewage sludge and limestone
US6302936B1 (en) Recycled soil
SU1599356A1 (ru) Способ получени искусственной почвы
WO2008133488A1 (es) Proceso de composteo semi -estático mejorado para la producción de un sustrato humectante de baja densidad, para su uso en viveros e invernaderos
DK166580B1 (da) Fremgangsmaade til omdannelse af ammoniumholdig gylle eller lignende
KR102308209B1 (ko) 친환경 절개지사면 녹화용 조성물의 제조방법
KR102159752B1 (ko) 법면 녹화용 친환경 녹생토 조성물 및 이를 이용한 친환경 법면 녹화 시공방법
CN114015451A (zh) 一种弱碱性土壤镉钝化剂及其应用
KR100612767B1 (ko) 폐자원의 재활용을 통한 식물 생육보조재 조성물
LT7017B (lt) Organinės trąšos sapropelio pagrindu ir jų gamybos būdas, panaudojant susmulkintas aukštapelkines durpes ir hidrogelį
Chhabra Reclamation and Management of Alkali Soils for crop production
RU2020144C1 (ru) Состав для рекультивации почв
KR100353923B1 (ko) 수화반응물질을 이용한 사면 녹화재 조성물 및 그 제조방법
CN115735712A (zh) 一种植被恢复用基质及其制备方法
PL236167B1 (pl) Sposób wytwarzania nawozów organicznych i nawóz organiczny wytworzony tym sposobem
RU2786219C1 (ru) Способ получения биопрепаратов
RU2808737C1 (ru) Способ получения техногенного почвогрунта
RU12916U1 (ru) Торфодерновой почвозаменяющий брикет для выращивания растений, преимущественно для сборного газона
RU2828738C1 (ru) Почвогрунт для придорожных полос
RU2540349C1 (ru) Способ получения органического удобрения
KR100429108B1 (ko) 불가사리를 이용한 퇴비 제조방법

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20030116